Vi e w p o i n t | 31 Jul 2026 07:21:07 ET │ 15 pages US Biotechnology and Pharmaceuticals GLP-1 TRx trends from the month and last week CITI'S TAKE We examined GLP-1 TRx trends over the past four weeks to assess y/y market changes. Collectively, TRx is 4.5% vs 0.6% prior as oral options broaden and reshape the market. Lilly's tirzepatide now holds 56.2% market share of total GLP-1 TRx, with share 0.5% over the four week period; compared to 48.4%/-1.1% last year. Comparatively, Novo's semaglutide has 37.1% ...